These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 32353608)

  • 1. Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies.
    Ueda M; Sekijima Y; Koike H; Yamashita T; Yoshinaga T; Ishii T; Ando Y
    J Neurol Sci; 2020 Jul; 414():116813. PubMed ID: 32353608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal.
    Ando Y; Waddington-Cruz M; Sekijima Y; Koike H; Ueda M; Konishi H; Ishii T; Coelho T
    Orphanet J Rare Dis; 2023 Oct; 18(1):323. PubMed ID: 37828588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hereditary transthyretin amyloidosis overview.
    Manganelli F; Fabrizi GM; Luigetti M; Mandich P; Mazzeo A; Pareyson D
    Neurol Sci; 2022 Dec; 43(Suppl 2):595-604. PubMed ID: 33188616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and natural history of different phenotypes in hereditary transthyretin amyloidosis: 40-year experience at a single Italian referral centre.
    Caponetti AG; Sguazzotti M; Accietto A; Saturi G; Ponziani A; Giovannetti A; Massa P; Ruotolo I; Sena G; Zaccaro A; Parisi V; Bonfiglioli R; Guaraldi P; Gagliardi C; Cortelli P; Galie N; Biagini E; Longhi S
    Eur J Prev Cardiol; 2024 May; 31(7):866-876. PubMed ID: 38204330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A natural history analysis of asymptomatic
    Coelho T; Conceição I; Waddington-Cruz M; Keohane D; Sultan MB; Chapman D; Amass L;
    Amyloid; 2022 Dec; 29(4):228-236. PubMed ID: 35730447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy.
    Schmidt HH; Barroso F; González-Duarte A; Conceição I; Obici L; Keohane D; Amass L
    Muscle Nerve; 2016 Sep; 54(3):353-60. PubMed ID: 27273296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations.
    Conceição I; Damy T; Romero M; Galán L; Attarian S; Luigetti M; Sadeh M; Sarafov S; Tournev I; Ueda M
    Amyloid; 2019 Mar; 26(1):3-9. PubMed ID: 30793974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis.
    Berends M; Brunger AF; Bijzet J; Kroesen BJ; Drost G; Lange F; Teunissen CE; In 't Veld S; Vrancken AF; Gans ROB; Hazenberg BPC; van der Zwaag PA; Nienhuis HLA
    Amyloid; 2024 Jun; 31(2):132-141. PubMed ID: 38477065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detailed clinical, physiological and pathological phenotyping can impact access to disease-modifying treatments in ATTR carriers.
    Beauvais D; Labeyrie C; Cauquil C; Francou B; Eliahou L; Not A; Echaniz-Laguna A; Adam C; Slama MS; Benmalek A; Leonardi L; Rouzet F; Adams D; Algalarrondo V; Beaudonnet G
    J Neurol Neurosurg Psychiatry; 2024 May; 95(6):489-499. PubMed ID: 37875336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays.
    Kaku MC; Bhadola S; Berk JL; Sanchorawala V; Connors LH; Lau KHV
    Amyloid; 2022 Sep; 29(3):184-189. PubMed ID: 35253562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular autonomic failure in hereditary transthyretin amyloidosis and TTR carriers is an early and progressive disease marker.
    Chiaro G; Stancanelli C; Koay S; Vichayanrat E; Sander L; Ingle GT; McNamara P; Carr AS; Wechalekar AD; Whelan CJ; Gillmore JD; Hawkins PN; Reilly MM; Mathias CJ; Iodice V
    Clin Auton Res; 2024 Jun; 34(3):341-352. PubMed ID: 38769233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three patients of transthyretin amyloidosis in a Japanese family with amyloidogenic transthyretin Thr49Ser (p.Thr69Ser) variant.
    Ikura H; Kitakata H; Endo J; Moriyama H; Sano M; Tsujikawa H; Sawano M; Masuda T; Ohki T; Ueda M; Kosaki K; Fukuda K
    Eur J Med Genet; 2022 Mar; 65(3):104451. PubMed ID: 35149236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma growth differentiation factor 15: a novel tool to detect early changes of hereditary transthyretin amyloidosis.
    Okada M; Misumi Y; Masuda T; Takashio S; Tasaki M; Matsushita H; Ueda A; Inoue Y; Nomura T; Nakajima M; Yamashita T; Shinriki S; Matsui H; Tsujita K; Ando Y; Ueda M
    ESC Heart Fail; 2021 Apr; 8(2):1178-1185. PubMed ID: 33381924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan.
    Ueda M; Yamashita T; Misumi Y; Masuda T; Ando Y
    Amyloid; 2018 Sep; 25(3):143-147. PubMed ID: 30486687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early detection of nerve involvement in presymptomatic TTR mutation carriers: exploring potential markers of disease onset.
    Romano A; Guglielmino V; Bisogni G; Di Paolantonio A; Truini A; Minnella AM; Sciarrone MA; Vitali F; Maceroni M; Galosi E; Sabatelli M; Luigetti M
    Neurol Sci; 2024 Apr; 45(4):1675-1684. PubMed ID: 37938457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.
    Sekijima Y; Ueda M; Koike H; Misawa S; Ishii T; Ando Y
    Orphanet J Rare Dis; 2018 Jan; 13(1):6. PubMed ID: 29343286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.
    Coelho T; Maurer MS; Suhr OB
    Curr Med Res Opin; 2013 Jan; 29(1):63-76. PubMed ID: 23193944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy.
    Dardiotis E; Kyriakides T
    Curr Neuropharmacol; 2023; 21(3):471-481. PubMed ID: 36366846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy].
    Sekijima Y
    Rinsho Shinkeigaku; 2014; 54(12):953-6. PubMed ID: 25672679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.
    Carroll A; Dyck PJ; de Carvalho M; Kennerson M; Reilly MM; Kiernan MC; Vucic S
    J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):668-678. PubMed ID: 35256455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.